Overview

A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women

Status:
Completed

Trial end date:
2018-05-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the bioequivalence of the hormones (ie, norelgestromin [NGMN] and ethinyl estradiol [EE]) from the transdermal contraceptive patch and to evaluate the adhesion of the transdermal contraceptive patch using the newly sourced adhesive component, as compared to the currently marketed EVRA patch.

Phase:

Phase 4

Details

Lead Sponsor:

Janssen Research & Development, LLC

Treatments:

Contraceptive Agents